Steven Lazarus's Net Worth
$598 Million
Who is Steven Lazarus?
Steven Lazarus has an estimated net worth of $598 Million. This is based on reported shares across multiple companies, which include IMPINJ INC, XCYTE THERAPIES INC, AMGEN INC, XTERA COMMUNICATIONS, INC., Trubion Pharmaceuticals, Inc, CELEBRATE EXPRESS, INC., ILLUMINA INC, ALNYLAM PHARMACEUTICALS INC, NeurogesX Inc, and FIRST CONSULTING GROUP INC.
SEC CIK
Steven Lazarus's CIK is 0001054117
Past Insider Trading and Trends
2004 was Steven Lazarus's most active year for acquiring shares with 7 total transactions. Steven Lazarus's most active month to acquire stocks was the month of June. 2004 was Steven Lazarus's most active year for disposing of shares, totalling 20 transactions. Steven Lazarus's most active month to dispose stocks was the month of September. 2011 saw Steven Lazarus paying a total of $2,999,999.92 for 2,616,279 shares, this is the most they've acquired in one year. In 2003 Steven Lazarus cashed out on 330,001 shares for a total of $1,360,105.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ALNYLAM PHARMACEUTICALS INC (ALNY) Snapshot price: $172.47
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
IMPINJ INC (PI) Snapshot price: $100.38
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
∞
| 1.37M |
$10.73 | $204.50 | 1.37M |
Jul 26
| |||
Form 4
|
∞
| 1.36M |
$11.66 | $68.32 | 1.36M |
Jul 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
NeurogesX Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +71.38% | 1.74M |
$1.65 | $2,877,906.90 | 4.19M |
Jul 21
| |||
Form 4
| +18.54% | 382.17K |
$6.18 | $2,361,810.60 | 2.44M |
Dec 24
| |||
Form 4
| +1,015.12% | 2.3M |
—
|
—
| 2.53M |
May 7
| |||
Form 4
|
∞
| 227K |
$11.00 | $2,497,000.00 | 227K |
May 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
XCYTE THERAPIES INC (CYCC) Snapshot price: $2.29
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 29
| |||
Form 4
|
∞
| 2.05M |
$8.00 | $1,500,000.00 | 2.05M |
Mar 19
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
AMGEN INC (AMGN) Snapshot price: $322.42
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 1.64K |
—
|
—
| 1.64K |
Mar 15
| |||
Form 4
| -6.28% | -10.00K |
$64.22 | -$642,200.00 | 149.34K |
Feb 25
| |||
Form 4
| -5.91% | -10.00K |
$64.01 | -$640,086.56 | 159.34K |
Feb 24
| |||
Form 4
| -5.58% | -10.00K |
—
|
—
| 169.34K |
Nov 21
| |||
Form 4
| -4.78% | -9.00K |
$68.00 | -$612,000.00 | 179.34K |
Sep 8
| |||
Form 4
| -0.53% | -1.00K |
$68.11 | -$68,105.00 | 188.34K |
Sep 3
| |||
Form 4/A
|
—
|
0
|
—
|
—
| 189.34K |
Aug 28
| |||
Form 4
| -5.28% | -10.00K |
$68.00 | -$680,000.00 | 179.34K |
Aug 12
| |||
No matching records found |